

January 20, 2023 | Issue 255

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



CMS <u>announced efforts</u> to reduce unnecessary antipsychotic use in nursing homes and improve transparency about citations... CMS <u>approved 12-month</u> <u>Medicaid post-partum coverage</u> in Alabama and North Dakota.

CMS data show Medicare Advantage enrollment has topped 30M... CMS announced 13.2M Medicare beneficiaries will be served through accountable care initiatives in 2023.

FDA denied accelerated approval to Eli Lilly's Alzheimer's drug donanemab.

An FDA official indicated <u>lab-developed diagnostic reform could be included</u> in pandemic preparedness authorization legislation or <u>pursued through</u> <u>rulemaking</u>.

Healthcare law and policy news

Treasury Department <u>began "extraordinary measures"</u> as the US reached its <u>statutory debt limit</u>.

MedPAC warned <u>Medicare drug price negotiation may increase some new drug</u> <u>costs</u>... Prescription drug purchasers <u>expect drug prices to average 8% annual</u> <u>growth over the next three years</u>; 19% believe newer, pricier therapies will drive the growth.

Ponder data show the <u>number of hospital mergers in 2022 (55)</u> was the lowest since 2009... STAT <u>reported on hospitals' 2023 plans</u> for growth and increasing market power... Gibbins Advisors reported <u>46 large healthcare</u> <u>bankruptcy filings (liabilities \$10M+) occurred</u> in 2022, <u>up 84% from 2021 (25)</u> and roughly even with 2020 (45).

HHS <u>reported the uninsured rate fell</u> from 11.1% in 2019 to 10.5% in 2021... CDC <u>reported 10.8% of individuals were in families having trouble paying</u> medical bills in 2021, down from 2019 (14%)... A <u>Gallup survey found 38% of</u> <u>respondents (or family members) delayed</u> medical treatment due to costs in 2022, a record high.

A <u>NEJM</u> study found a preventable adverse event occurred in 6.8% of sampled 2018 patient admissions... A <u>JAMA</u> study concluded prescription drugs promoted in direct-to-consumer advertising were not any better than existing therapies... An <u>ICER</u> analysis found nearly all major health plans provide "fair access" to 19 selected therapies, although just 70% have fair/transparent cost-sharing policies... A <u>study found</u> just <u>19% of selected</u> <u>hospitals</u> fully complied with CMS price transparency requirements... CDC reported <u>opioids</u> were prescribed at 8.1% of ED discharges in 2019-2020, down from 12.2% in 2017-2018.

KFF reported, despite a surge in telehealth use, <u>private insurers paid similarly</u> <u>for telehealth and in-person</u> professional services in 2020.

Pfizer will sell <u>its full portfolio of medicines</u> to 45 low-income countries at a not-for-profit price.

-0

Ø

Special Section: COVID-19 and Other Respiratory Illnesses News

GAO <u>recommended HHS improve oversight of research</u> into "enhanced potential pandemic pathogens."

HHS announced <u>David Kessler is leaving his position</u> as COVID Chief Science Officer.

A <u>study found hybrid immunity</u> (mixed protection provided by COVID-19 vaccination and infection) was <u>97% effective at preventing severe disease or hospitalization</u> for up to 12 months after infection or initial immunization; previous infection with no vaccination was 75% effective against severe disease or hospitalization a year out.

OIG reported <u>more than 1,300 nursing homes had COVID-19 infection rates of</u> <u>75% or more</u> in 2020 and recommended changes to better protect residents and prepare for future health emergencies.

Moderna reported its <u>RSV vaccine was 83.7% effective at preventing disease</u> in older adults.

The World Health Organization <u>launched an initiative to accelerate</u> <u>development, licensing, and use</u> of a novel tuberculosis vaccine.



Questions or comments, please send to us-hclspractice@kpmg.com.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please <u>click here</u>. If you wish to unsubscribe from all KPMG communications, please <u>click here</u>.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.